Can High-Phenolic Galician EVOO Improve Blood Sugar in Type 2 Diabetes?
Here’s the real question: if you give people with type 2 diabetes a genuinely phenolic-rich olive oil for 24 weeks, do you get a meaningful metabolic shift, or just another nutrition story that sounds better than it performs? The OILDIABET randomized trial in Food & Function is refreshingly honest. It did not turn olive oil into a miracle drug. It did, however, produce a clean signal on insulin resistance, with stronger improvements in the people most likely to benefit, especially those with obesity and those already insulin resistant.
Study Overview
This was not a vague “olive oil is healthy” exercise. The oil was chemically dense, with 23 identified phenolic compounds and a secoiridoid-heavy profile. Oleocanthal measured 201.35 mg/kg and oleacein 196.02 mg/kg, while total phenolics were about 1,000 mg/kg. That matters because a bland olive oil and a phenolic-rich EVOO are not the same intervention, biologically or clinically.
Key Findings: Small on Glucose, Better on Insulin Resistance
In the full sample, the control group improved a little too, which is exactly why nutritional trials are harder than supplement brochures make them sound. Both groups lost some weight, and both groups were followed closely. The intervention arm still had the cleaner metabolic signal, but the effect size was not dramatic. This is a real result, not a fantasy result.
The strongest whole-cohort change was insulin resistance, not fasting glucose. Fasting glucose itself was not significant in the full sample, and the lipid panel refused to budge. That makes the study look more like a targeted insulin-sensitivity trial than a broad cardiometabolic reset.
The subgroup data are where the paper gets more interesting. In the obesity subgroup, the intervention lowered fasting glucose from 120.5 to 117.0 mg/dL (p = 0.049), estimated average glucose from 143.32 to 138.21 mg/dL (p = 0.031), and HbA1c from 6.63% to 6.44% (p = 0.031). In the insulin-resistant subgroup, fasting insulin fell from 16.70 to 12.50 μU/mL (p = 0.019) and HOMA-IR from 5.30 to 3.70 (p = 0.029). In obese participants, the share with HOMA-IR > 3.8 dropped to 20.6% in the intervention group versus 52.2% in control (p = 0.013).
Mechanism: Why This Oil Had a Plausible Shot
1. It was loaded with secoiridoids
Oleocanthal and oleacein are not decorative molecules. They are among the best-known olive phenolics for anti-inflammatory and antioxidant signaling, and the paper explicitly points to them as candidate drivers of improved glucose handling.
2. Prior work suggests glucose absorption may slow down
The authors cite earlier Galician olive-oil research showing stronger α-glucosidase inhibition than acarbose in vitro. That matters because slowing carbohydrate digestion is one of the cleanest ways a food matrix can influence post-meal glucose.
3. Less inflammation, better insulin signaling
The biologic story is familiar but still plausible: lower inflammatory tone, better oxidative balance, more nitric-oxide availability, and less interference with insulin receptor signaling. That is a far more credible mechanism than the usual “healthy fat” hand-wave.
Context: This Fits the Olive-Oil Literature, With Caveats
The broader olive-oil literature has always been mixed in one very specific way: food-based EVOO tends to look more promising than isolated claims, but the size of the effect depends heavily on phenotype, dose, duration, and what the control diet is doing in the background. This trial fits that pattern nicely.
It also lines up with earlier human work suggesting polyphenol-rich EVOO can help glycemic markers in people with overweight or diabetes, while less phenolic oils or shorter trials often produce weaker, noisier results. The key message is not that olive oil is uniformly glucose-lowering. It’s that phenolic density probably matters, and the people with the worst metabolic starting point have the most to gain.
That is the right way to read this paper. It confirms the direction of prior evidence, but it does not overclaim. In a field full of overconfident food marketing, that restraint is a strength.
Practical Takeaway
- • If you have type 2 diabetes, high-phenolic extra virgin olive oil looks like a sensible replacement for lower-quality fats, not a standalone treatment.
- • The clearest benefit here was insulin resistance, especially in people with obesity or existing insulin resistance.
- • Do not expect olive oil alone to fix cholesterol or blood pressure, because this study did not show that.
- • If you buy EVOO for health, phenolic richness is the detail worth caring about, not just the generic label.
Limitations
The effect was modest
The whole-cohort change in HOMA-IR was statistically significant, but small in absolute terms.
Subgroups were underpowered
The obesity and insulin-resistance analyses are interesting, but the authors correctly warn that these slices of the sample were too small for hard conclusions.
Control diet was not inert
Participants were followed closely, and the control group still changed over time, which can dilute between-group differences.
No hard event outcomes
This was a biomarker trial, not a complications trial, so it cannot tell us whether the oil changes real-world diabetes outcomes.
Still, the trial was well-designed for what it asked. It was long enough to matter, used randomization, had high completion, and actually tracked adherence. That puts it a step above the usual nutrition-paper noise.
Our Take
I like this study because it is specific. It doesn’t pretend every olive oil is the same, and it doesn’t pretend a dietary intervention is magic just because it sounds Mediterranean. The authors measured a real product, tested real people, and showed a real, if modest, metabolic signal.
The downside is obvious too: the headline win is not dramatic, and the classic cardiometabolic endpoints stayed stubbornly flat. So this is not a paper that makes olive oil look like a diabetes drug. It makes high-phenolic EVOO look like a useful food with the strongest upside in the exact people you’d expect, those already struggling with insulin resistance.
Bottom line: strong on plausibility, decent on trial quality, modest on effect size, and useful in real life. That is a good nutrition paper.
References
1. Figueiredo-González M, et al. Exploring Galician phenolic-rich olive oil as a glycemic control strategy: the OILDIABET randomized trial. Food & Function. 2025;16(15):6213-6230. doi:10.1039/d5fo00873e. PMID: 40678895. PubMed →
2. Santangelo C, et al. High-phenolic extra virgin olive oil and glycemic control in type 2 diabetes. Randomized crossover trial, 2016.
3. Ruíz-García A, et al. EVOO versus common olive oil in adults with obesity and prediabetes. 2023.
4. Silveira M, et al. Traditional diet plus EVOO in adults with obesity and type 2 diabetes. 2022.
Read the paper
The full article is here: RSC Food & Function page.
The short version
High-phenolic Galician EVOO gave a modest but real insulin-resistance signal in type 2 diabetes, with the best results in obese and insulin-resistant participants.
See all research →